GPC Biotech Patents Satraplatin Drug in Europe, Shares Rise Bloomberg - The patent is valid until 2025. GPC rose 31 cents, or 12.6 percent, to 2.78 euros in Frankfurt trading, giving the company a market value of 104 million ... |
Saturday, June 14, 2008
GPC Biotech Patents Satraplatin Drug in Europe, Shares Rise - Bloomberg
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment